BioSpace News Archive

The US Food and Drug Administration, FDA, approves NeuroVive’s IND (Investigational New Drug) application, enabling clinical studies in the US with the company’s drug candidate NeuroSTAT.

André Lussier, Chairman of the Board of Directors of Lussier Dale Parizeau, is pleased to appoint Michel Laurin as President and Chief Operating Officer of the company.

Kraig Labs adds first biological engineer to R&D team bringing extensive spider silk experience

Accuray Incorporated (NASDAQ: ARAY) announced today that physicians at the Froedtert & the Medical College of Wisconsin (“MCW”) Clinical Cancer Center at Froedtert Hospital in Milwaukee, Wisconsin have treated the first cancer patient in the world, a 45-year-old man with lung cancer, using the Radixact® System with Synchrony® motion tracking and correction technology

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) today announced the launch of its online ordering system for the direct fulfillment of medicinal cannabis orders.

IQ4I Research published a report on “Drug Discovery Outsourcing (DDO) Global Market – Forecast To 2027".

Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast Cancer Conference Expert Panel has recommended the Oncotype DX Breast Recurrence Score® test to guide chemotherapy treatment use for patients with hormone-receptor positive,

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, were published online ahead of print in The Lancet.

The Primary Ciliary Dyskinesia Foundation (PCDF) has engaged Prometheus Research to deliver the informatics expertise and core technology that will empower the PCDF to accelerate its mission to advance research, diagnosis, care, and ultimately, find a cure for PCD.

CM-101 was safe and well tolerated using both IV and SC formulations